New in PMC Update on PMC Article Dataset Distribution Changes As announced on February 12, major changes to PMC's Article Dataset Distribution Services are underway
Given the lack of long-term research involving TB-500, researchers ability to draw meaningful conclusions regarding TB-500s long-term safety is limited, suggesting further investigation is required
Despite its small size, KPV demonstrates potent anti-inflammatory properties and exhibits high hydrophilicity, though this characteristic results in poor skin penetration when applied topically
Both categories tolerate standard refrigeration well, making combined storage straightforward
View Study [2]"Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide" Enebo LB et al., 2021 Finding: Phase 1b trial demonstrated that combining cagrilintide with semaglutide 2.4mg resulted in up to 17.1% weight loss at 20 weeks, with the combination being well-tolerated